- Home
- Publications
- Publication Search
- Publication Details
Title
CDK inhibitors from past to present: A new wave of cancer therapy
Authors
Keywords
-
Journal
SEMINARS IN CANCER BIOLOGY
Volume 88, Issue -, Pages 106-122
Publisher
Elsevier BV
Online
2022-12-22
DOI
10.1016/j.semcancer.2022.12.006
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Resistance to CDK4/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer
- (2022) Marios C. Papadimitriou et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: synthesis and clinical application
- (2021) Shuai Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update
- (2021) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer
- (2021) Chao Li et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)
- (2021) G.N. Hortobagyi et al. ANNALS OF ONCOLOGY
- 228MO PALOMA-4: Primary results from a phase III trial of palbociclib (PAL) + letrozole (LET) vs placebo (PBO) + LET in Asian postmenopausal women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (ABC)
- (2021) B. Xu et al. ANNALS OF ONCOLOGY
- Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis
- (2021) Elizabeth M. Salvo et al. BREAST
- The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time
- (2021) Mayu Ono et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Cell cycle control in cancer
- (2021) Helen K. Matthews et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study
- (2021) Antoinette R. Tan et al. CLINICAL CANCER RESEARCH
- Cyclin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment
- (2021) Oana-Maria Thoma et al. Frontiers in Pharmacology
- The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer
- (2020) Scott F. Schoninger et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of cyclin-dependent kinases by AT7519 enhances nasopharyngeal carcinoma cell response to chemotherapy
- (2020) Xin Wei et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression.
- (2020) Amy Jo Chien et al. JOURNAL OF CLINICAL ONCOLOGY
- Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies
- (2020) Xia-qing Xu et al. ACTA PHARMACOLOGICA SINICA
- Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer
- (2020) Sheelagh Frame et al. PLoS One
- CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy
- (2020) Anne Y Lai et al. Journal for ImmunoTherapy of Cancer
- Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo
- (2019) Yudi Xiong et al. BIOMEDICINE & PHARMACOTHERAPY
- Role of cyclin‐dependent kinases (CDKs) in hepatocellular carcinoma: Therapeutic potential of targeting the CDK signaling pathway
- (2019) Shen Shen et al. HEPATOLOGY RESEARCH
- P53 pathway is a major determinant in the radiosensitizing effect of Palbociclib: Implication in cancer therapy
- (2019) D.M. Fernández-Aroca et al. CANCER LETTERS
- Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial
- (2019) Antoinette R Tan et al. LANCET ONCOLOGY
- FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer
- (2018) Anand Shah et al. CLINICAL CANCER RESEARCH
- Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
- (2018) Silvia Paola Corona et al. Drug Design Development and Therapy
- CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest
- (2018) Shom Goel et al. TRENDS IN CELL BIOLOGY
- Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer in PALOMA-3
- (2018) Massimo Cristofanilli et al. EUROPEAN JOURNAL OF CANCER
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
- (2018) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion
- (2017) Shenghui He et al. Science Translational Medicine
- Biological functions of CDK5 and potential CDK5 targeted clinical treatments
- (2017) Alison Shupp et al. Oncotarget
- Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
- (2016) Romualdo Barroso-Sousa et al. Breast Care
- Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data
- (2016) Neelima Vidula et al. Clinical Breast Cancer
- A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
- (2016) J. R. Infante et al. CLINICAL CANCER RESEARCH
- Design strategies, structure activity relationship and mechanistic insights for purines as kinase inhibitors
- (2016) Sahil Sharma et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma
- (2016) Julien Bollard et al. GUT
- Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression
- (2016) J. E. Bisi et al. MOLECULAR CANCER THERAPEUTICS
- Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
- (2016) P. Chen et al. MOLECULAR CANCER THERAPEUTICS
- PALOMA-2 — hope beyond the threshold
- (2016) Diana Romero Nature Reviews Clinical Oncology
- Treating cancer with selective CDK4/6 inhibitors
- (2016) Ben O'Leary et al. Nature Reviews Clinical Oncology
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
- (2016) A. Patnaik et al. Cancer Discovery
- Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer
- (2015) Natalia J. Sumi et al. ACS Chemical Biology
- Cyclin dependent kinase (CDK) inhibitors as anticancer drugs
- (2015) Concepción Sánchez-Martínez et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Abstract 1650: CYC065, a novel CDK2/5/9 inhibitor: detailed mechanistic studies, determinants of sensitivity and synergistic combinations
- (2015) Chiara Saladino et al. CANCER RESEARCH
- Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma
- (2015) M. E. M. Dolman et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment
- (2015) T. VanArsdale et al. CLINICAL CANCER RESEARCH
- Palbociclib: First Global Approval
- (2015) Sohita Dhillon DRUGS
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia
- (2015) J Flynn et al. LEUKEMIA
- Abstract B31: A Phase I study of single-agent ribociclib in Japanese patients with advanced solid tumors
- (2015) Yasuhide Yamada et al. MOLECULAR CANCER THERAPEUTICS
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting Breast Cancer with CDK Inhibitors
- (2015) Erica L. Mayer Current Oncology Reports
- Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway
- (2015) Ge Qin et al. Oncotarget
- Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)
- (2015) Richard S. Finn et al. CANCER RESEARCH
- Abstract CT232: Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer
- (2015) Amita Patnaik et al. CANCER RESEARCH
- A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177
- (2014) E X Chen et al. BRITISH JOURNAL OF CANCER
- Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients
- (2014) Claire Fabre et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
- (2014) A. DeMichele et al. CLINICAL CANCER RESEARCH
- Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
- (2014) Lawrence M. Gelbert et al. INVESTIGATIONAL NEW DRUGS
- Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6- Reactivating Rb in cancer.
- (2014) S. Kim et al. MOLECULAR CANCER THERAPEUTICS
- Cyclin-dependent kinases
- (2014) Marcos Malumbres GENOME BIOLOGY
- Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer
- (2013) Monica M. Mita et al. Clinical Breast Cancer
- Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
- (2013) J. Rader et al. CLINICAL CANCER RESEARCH
- A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
- (2013) John J Nemunaitis et al. Journal of Translational Medicine
- Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer
- (2013) Joe J. Stephenson et al. LUNG CANCER
- Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features
- (2012) J A Woyach et al. LEUKEMIA
- Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors
- (2011) Stuart C. Wilson et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
- (2011) G K Schwartz et al. BRITISH JOURNAL OF CANCER
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
- (2011) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
- (2011) Gottfried E. Konecny et al. CLINICAL CANCER RESEARCH
- The CDK inhibitors in cancer research and therapy
- (2011) Jonas Cicenas et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Progressive Activation of CyclinB1-Cdk1 Coordinates Entry to Mitosis
- (2010) Olivier Gavet et al. DEVELOPMENTAL CELL
- Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies
- (2010) Christophe Le Tourneau et al. EUROPEAN JOURNAL OF CANCER
- Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma
- (2010) Wei-Gang Tong et al. JOURNAL OF CLINICAL ONCOLOGY
- Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
- (2010) David Parry et al. MOLECULAR CANCER THERAPEUTICS
- Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours
- (2009) D. S. Boss et al. ANNALS OF ONCOLOGY
- Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines
- (2009) M. S. Squires et al. MOLECULAR CANCER THERAPEUTICS
- Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms
- (2009) A Satyanarayana et al. ONCOGENE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started